The global award recognises HayMax innovative product and expansion into overseas markets
HayMax, maker of the organic drug-free allergen barrier balm, has been honoured in the M&A Today Global Awards 2024, winning in the category of Leading Pharmaceutical Company.
These awards celebrate ‘unparalleled excellence globally’, with participation from over 163 countries.
HayMax stated that its achievement in the M&A Today Awards underscores the company’s “dedication and strategic innovation in the industry,” distinguishing it as a global leader.
Max Wiseberg, Managing Director of HayMax, expressed his delight stating “This is a great achievement for a small company to win on a global scale.”
He said that this global award is a recognition of their “innovative product and expansion into overseas markets” from their traditional UK base.”
The company noted that its focus on prevention sets itself apart from most other hay fever treatments and remedies.
The balm aims to stop pollen from entering the body before it can cause a reaction, rather than treating symptoms after they occur. This simple yet effective approach has earned HayMax a loyal following.
Over nearly two decades, the company has won more than 60 awards, including the 2023 Soil Association BOOM Award, British Made Award, Enterprise Award, BizzieBaby Award, Global 100 Award, and Corporate America Today Annual Award.
The M&A Today Global Awards are known for their thorough and objective selection process, which ensures that only truly exceptional firms are recognized.
The selection process is rigorous, with the assessment stage involving a combination of self-submission and third-party nominations.
Organisers conduct an in-depth analysis of the company’s domestic and international activities, focusing on strategic depth and complexity to form a list of elite firms.
An expert panel of independent judges then reviews this list, evaluating the strategic nature and complexity of projects, operational scale, speed, budget efficiency, and innovative approaches.
